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Summary In a study of DNAs from 100 breast cancer patients and 100 controls, there were no differences in
the frequencies of common or rare alleles at the Harvey ras (c-Ha-ras) locus on chromosome 11. However,
one Ha-ras allele was deleted from the tumour DNA in 14 of 65 informative patients. Loss of a Ha-ras allele
correlates with paucity of oestrogen receptor protein and with increased tumour size at presentation, but is
not associated with microscopic evidence of lymph node invasion. The findings on Ha-ras and other
informative loci are consistent with the possibility that a tumour suppressor gene involved in the early stages
of breast cancer is located on the short arm of chromosome 11.
The human Ha-ras oncogene, homologous to the trans-
forming sequence of the Harvey murine sarcoma virus, has
been assigned to the short arm of chromosome 11 (McBride
et al., 1982). On the 3' side of the gene lies a non-coding
region made up of a variable number of repeated sub-units
(Capon et al., 1983). Digestion with the restriction enzyme
Bam HI generates a restriction fragment length poly-
morphism with 4 common and several rarer alleles. Krontiris
et al. (1985) have reported an increased frequency of rare
alleles in patients with a variety of solid tumours and
haematological malignancies; their series included a small
number of breast cancers. This finding would imply that an
inherited predisposition to cancer is linked to alleles at the
Ha-ras locus. Several subsequent studies have sought to test
Krontiris' hypothesis as applied to lung cancer (Heighway et
al., 1986), myelodysplasia (Thein et al., 1986), colonic adeno-
carcinoma (Ceccherini-Nelli et al., 1987), familial melanoma
(Gerhard et al., 1987; Hayward et al., 1988) and breast
cancer (Lidereau et al., 1986). Only in the last two of these
has supporting evidence been forthcoming (Lidereau et al.,
1986; Hayward et al., 1988). However one group has
recorded that a proportion of breast tumours, from patients
constitutionally heterozygous at the Ha-ras locus, express
only one allele or show a marked disparity in the intensity of
the two allelic bands, suggesting that most or all of the
tumour cells have undergone loss of a part of chromosome
1lp (Theillet et al., 1986; Ali et al., 1987). Reduction to
homo- (or hemi-) zygosity at specific genetic loci was
recognised initially in retinoblastoma and subsequently in
several other tumours (Knudson, 1971; 1985). The loci
involved are believed to be sites of tumour suppressor genes
or 'anti-oncogenes' which are relevant both to somatic events
giving rise to sporadic tumours and to genetic predisposition
to cancers (Lancet, 1988). In view of the potential impor-
tance of these issues for breast cancer screening programmes
we have undertaken a survey of Ha-ras alleles in a cohort of
100 breast cancer patients.
with T4 tumours or with distant metastases at presentation,
were excluded, as they are usually treated by chemotherapy
in the first instance. The surgical procedures performed were
either modified Patey mastectomy with axillary clearance, or
wide local excision with axillary lymph node sampling. The
resected specimen was immediately examined by the patholo-
gist, tumour diameter measured in mm, and blocks taken for
histological examination and for oestrogen receptor protein
assay. The remainder was frozen on dry ice for later DNA
extraction.
Lymph nodes were processed and examined for micro-
scopic metastatic invasion. Tumours were classified into
histological types as previously reported (Page & Anderson,
1988). Oestrogen receptor concentration was determined
immediately by a saturation analytical method with sepa-
ration of free and bound hormone using Dextran-coated
charcoal adsorption as previously described (Hawkins et al.,
1981). Samples from patients who had received Tamoxifen
were rechecked by enzyme immunoassay (Leclercq et al.,
1986). One hundred fresh placental samples have also been
collected to act as a panel of normal controls representative
of the local Edinburgh population. Permanent lymphoid cell
lines were established from many of the blood samples by
transformation in vitro with Epstein Barr virus. DNA was
extracted from tumour and placental tissues and from blood
and lymphoid cell lines (Steel, 1984). Ten ,ug aliquots of
genomic DNA were digested to completion with Bam HI
(Roberts et al., 1977) (Boehringer, Mannheim GmbH),
electrophoresed through 0.8% agarose, transferred to nylon
membranes (Hybond, Amersham) and hybridised according
to the manufacturer's instructions with the Harvey ras probe
pEj (Shih & Weinberg, 1982), nick translated to a specific
activity of 5 x 107-1 x 108cpm ug- (Rigby et al., 1977).
After hybridisation, filters were washed at 65°C with
0.1XSSC (15mM Na Cl, 1.5mM NA3 citrate, 0.1% Na PPi,
0.1% SDS) and exposed to Kodak X-Ar film at -70°C for
7-14 days, with intensifying screens. Similar procedures were
followed with other probes and restriction enzymes as tabu-
lated below.
Patients and methods
Tumour and venous blood samples have been collected from
100 consecutive patients with histologically proven breast
cancer, prior to any treatment (apart from the anti-oestrogen
tamoxifen). All patients had presented with palpable breast
lumps and were referred by their general practitioners to the
breast clinic in the Royal Infirmary of Edinburgh. Patients
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Results
Allelic frequency
The four major c-Ha-ras Bam HI alleles A,-A4, together
with one rare variant A', are shown in Figure 1.
Table I shows the relative frequencies of these alleles in
blood and/or lymphoid cell line DNA from 100 breast
cancer patients and in DNA from 100 placentae.
There was no significant difference between breast cancer
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Figure 1 Alleles of c-Ha-ras (Bam HI digests) from four placen-
tal DNA samples. The left hand track of this Southern Blot
contains a 'doublet' of allele A1 and the rare variant A'
Table I Bam HI alleles of Harvey ras locus
100 Breast
cancer patients 100 Placentae
Number % Number %
A1 126 63.0 135 67.5
A2 25 12.5 27 13.5
A3 23 11.5 19 9.5
A4 19 9.5 15 7.5
Rare allelesa 7 3.5 4 2.0
aA1 and A"... slightly smaller and larger respectively than A1
patients and controls in the frequencies of rare Harvey ras
alleles; nor was there any shift in the distribution of common
alleles between the two groups.
Allele loss in tumours
Complete or partial loss of a c-Ha-ras allele was established
by comparing paired tumour DNA and white blood cell
DNA samples from the same patients (Figure 2).
The one hundred tumours analysed fall into the following
three categories. No allelic loss at the Ha-ras locus (51
tumours), loss of one allele (14 tumours) and uninformative,
because the patient was constitutionally homozygous (35
tumours).
There was no preferential loss or retention of any of the
four common alleles and our present analysis does not allow
us to determine the maternal or paternal derivation of a
deleted allele. We found no significant correlation between
allelic loss and menopausal status, age, or history of an
affected first degree relative. However, as shown in Table II,
there was a significant correlation between loss of a Ha-ras
allele and paucity of oestrogen receptor protein; absence of
oestrogen receptor being a well-recognised index of poor
prognosis (Croton et al., 1981; Moore et al., 1983; Williams
et al., 1987).
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Figure 2 Bam HI digests of tumour (T) and blood leukocyte (B)
DNA from the same patient, probed with c-Ha-ras and com-
pared with three placental controls. Note that alleles A1 and A3
are of equal intensity in B but allele A1 is almost absent from
the tumour sample.
There was also a significant correlation between tumour
size and allelic loss as shown in Figure 3.
There was no significant correlation between allelic loss
and pathological lymph node involvement, vascular invasion
or histological type of tumour.
In order to assess the specificity of loss of the Harvey ras
allele we have examined up to 5 other loci on the short arm
of chromosome I1, comparing tumour DNA with lympho-
blastoid cell line DNA from the same patient, as detailed in
Table III.
Heterozygosity was found on a total of 49 occasions and
the corresponding tumours had lost an allele in 19 cases
(38.8%). Nineteen tumour/cell line pairs have been fully
characterised for all 5 loci and allelic loss at one or more has
been found in 10 (53%).
We have also studied one informative locus (pepsinogen)
on the long arm of chromosome II and three at other
chromosomal sites (5q, 6p and 17q). Of 67 instances where
the patient was constitutionally heterozygous allele loss in
the tumour was found outside of the lp region on only one
occasion (Table IV).
Discussion
These results, in agreement with several published studies
(Krontiris et al., 1985; Heighway et al., 1986; Thein et al.,
1986; Ceccherini-Nelli et al., 1987; Gerhard et al., 1987)
demonstrate that rare Ha-ras alleles can be identified in the
normal population. We have found no evidence for an
increased frequency of rare alleles in breast cancer patients,
contradicting both Krontiris' initial report (Krontiris et al.,
1985) and the findings of a subsequent larger series
(Lidereau et al., 1986) in which rare alleles were identified in
41% of breast cancer patients. Heighway et al. (1986)
reported a preponderance of the A4 allele in patients with
non-small-cell lung carcinoma, but several other studies have
failed to find evidence of linkage in myelodysplasia (Thein et
al., 1986), colorectal adenocarcinoma (Hayward et al., 1988)
or familial melanoma (Gerhard, 1987). Lidereau's study on
breast cancer patients was performed on breast tumour
material which had been stored for up to 7 years, while the
controls were fresh blood samples from unaffected indiv-
iduals. Wyllie et al. (1988) has suggested that prolonged
storage could lead to the identification of spurious 'rare'
alleles, and we have therefore used DNA from white blood
cells or lymphoblastoid cell lines, as well as tumour material.
In contrast to these negative findings, the observation that
a substantial proportion of breast cancers have lost one c-
Ha-ras allele confirms the recent report of Theillet et al.
(1986) and lends some support to the hypothesis that the
Ha-ras locus may be involved in breast cancer, albeit on a
rather different theoretical basis.
Knudson's 'two hit' hypothesis (Knudson, 1971) provides
a link between the molecular mechanisms underlying familial
and sporadic forms of the same type of cancer. In sporadic
cancer, a cell undergoes a somatic mutation, which must
then be followed by a second event to express the malignant
phenotype, either a second somatic mutation or loss of the
unmutated allele by non-disjunction or deletion.
Following the localisation of the retinoblastoma gene to
13q14 (Cavenee et al., 1983) comparable deletions at other
sites have been reported in a variety of tumours, including
Wilms' tumour (Koufos et al., 1985), lung cancer (Kok et
al., 1987) and acoustic neuroma/meningioma (Seizinger et
al., 1986).
The present findings raise the question 'Is the reduction to
homozygosity of the Harvey ras gene in breast cancer merely
an indication that there has been a deletion somewhere on
chromosome II and is there another gene in the region
much more directly involved in the disease?' Ali and collea-
gues (1987) recently reported a total of 14 allele losses,
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Table II Relationship between loss of a c-Ha-ras allele and oestrogen receptor
level in 61 breast tumours
ER poor/-ve ER moderate/rich
<20fmolmg-1 protein >20fmolmg-1 protein (20)
Allelic loss 8 6
No allelic loss 10 37
P= <0.02.
No. Loss n = 51
Unknown - 10%
Table III Details of allelic losses on lIp in breast tumour DNA
compared with corresponding lymphoid cell line DNA
Tumour/
cell line
pair
Ha-ras P-globin
*1 *2
1 a- u a-
2 a- a- u
3 a- u u
4 a- u u
5 a- u u
6 a- u u
7 a- ab u
8 a- ab a-
30 Unknown - 7%
0-9 20-29 40-49 60-69 80-89
10-9 30-39 50-59 70-79 90-99
Tumour size in m.m.
Figure 3 Distribution of primary tumour size (greatest diameter
mm) in relation to Ha-ras allele status.
cancers from 9 patients, not all of whom were analysed for
every locus. We find reduction to hemizygosity of several
sequences other than Harvey ras on the same chromosome
arm, at least one locus being involved in 10 of 19 tumours
(53%), a frequency even higher than the corresponding
figure for Ha-ras (21.5%) and certainly much higher than
for informative loci outside llp (1 of 67 informative loci, in
27 breast tumours). It might be unwise to extrapolate from
the present data, for example, to suggest that llp deletions
can be inferred in almost 50% of primary breast cancers
since only 19 tumours have been analysed in detail so far
and they include 8 already known to have lost a Ha-ras
allele. Nevertheless there has clearly been a substantial
frequency of DNA lesions within the short arm of chromo-
some 11 in our tumour material. The simplest interpretation
is that a single mitotic recombination event has caused loss
of all loci distal to the breakpoint which, in some instances,
must have been on the centromeric side of the most proxi-
mal sequence examined, P1 F9, at llpl3. At least three of
the tumours studied, however, show patterns of allele loss
incompatible with this simple mechanism since one or more
loci on the telomeric side of the region of hemizygotisation
remain heterozygous and in one case (No. 8, Table III) there
were two regions of hemizygotisation separated by a locus
that remains heterozygous. It is necessary, therefore, to
invoke either multiple mitotic recombination events, localised
chromosome deletions, partial inversions or even more com-
plex rearrangements. More extensive mapping studies are
required to resolve the issues raised by these observations
and analysis is now being extended to cover all one hundred
tumours in our series. One objective is to identify the
smallest region of chromosome 1 p that is consistently
included in any deletion that can be mapped. Such a region
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Telomere
15-515.4 15-1 15-
ab=informative, not lost; u=uninformative; a- = allele loss.
'a' and 'b' should not be taken to refer to specific alleles.
*1=Shih & Weinberg (1982); *2=Deisseroth et al. (1978);
*3=Naylor et al. (1982); *4=Hoppener et al. (1984); *5,6=Glaser
et al. (1985), Watkins et al. (1985); *7,8=Porteous et al. (1987),
Boyd et al. (submitted).
might then be the site of a putative tumour suppressor gene
(Friend et al., 1988).
This of course does not preclude the specific involvement
of other regions of the genome not examined in the present
study and it is quite possible that two or more putative anti-
oncogenes are involved in breast cancer (Lancet editorial,
1988). It is relevant to note that loss of heterozygosity has
been reported on 13q in 6 out of 10 ductal breast cancers
(Lundberg et al., 1987).
We find that loss of a Ha-ras allele correlates with paucity
of oestrogen receptor protein and with larger tumour size at
presentation, but there is no correlation between patho-
logical lymph node involvement and loss of a Ha-ras allele.
Theillet et al. (1986) concluded that Ha-ras allelic loss was
significantly linked to parameters of tumour aggressiveness
since, in their material there were correlations between allelic
loss and paucity of oestrogen receptor protein, histological
grade and early occurrence of distant metastasis.
Table IV
Gene or No. No. No
probe Designation Localisation Restriction enz Refa examined informative lost
Pepsinogen pH PEP 1lq12 EcoRl 1,2 24 20 0
Erb A2 pHeA2 17q21.3 BamHl 3 20 11 0
MHC Class II pll-B-4 6p21.3 EcoRl 4 21 21 0
iMS8 D8 S43 Sq 34qter Hin Fl 5,6 18 15 1
Total 67 1
a-12 =Taggart et al. (1985; 1987); 3 =Gosden et al. (1986); 4 =Gustafsson et al. (1984); 5,6 =Solomon et al. (1987), Wong
et al. (1987).
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Of the six breast tumours identified in this series as
uninformative or heterozygous for c-Ha-ras, but showing
loss of an allele at one or more loci elsewhere on lIp (cases
9, 13, 14, 15, 18 and 19, Table III), five had low or absent
oestrogen receptor. The correlation between this prognostic
feature and hemizygotisation of sequences somewhere on lp
therefore does not seem to be exclusive to the Harvey-ras
locus. Although such a conclusion must be tentative until a
larger number of tumours has been analysed in similar
detail, the suggestion is that c-Ha-ras serves as a relatively
inefficient index of hemizygotisation of a specific locus some
distance away.
It will be of great importance to map that putative locus
and thereafter to reassess the clinico-pathological correla-
tions already established, to see if information of prognostic
value can be obtained from DNA analysis of tumours at
presentation. The clinical relevance of such findings will be
established by follow up of our patient cohort to gather data
on disease-free interval and long-term survival. Ultimately
the objective is to define the gene itself and to establish the
mechanism whereby it contributes to the evolution of breast
cancer.
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